Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone by Aldridge, S E et al.
Vascular endothelial growth factor acts as an osteolytic factor in
breast cancer metastases to bone
SE Aldridge*,1, TWJ Lennard
1, JR Williams
1 and MA Birch
1
1The School of Surgical Sciences, The Medical School, Framlington Place, University of Newcastle upon Tyne NE2 4HH, UK
Vascular endothelial growth factor (VEGF) is a proangiogenic cytokine that is expressed highly in many solid tumours often correlating
with a poor prognosis. In this study, we investigated the expression of VEGF and its receptors in bone metastases from primary
human breast tumours and further characterised its effects on osteoclasts in vitro. Breast cancer metastases to bone were
immunohistochemically stained for VEGF, its receptors VEGFR1 and 2 (vascular endothelial growth factor receptor 1 and 2),
demonstrating that breast cancer metastases express VEGF strongly and that surrounding osteoclasts express both VEGFR1 and
VEGFR2. RAW 264.7 cells (mouse monocyte cell line) and human peripheral blood mononuclear cells (PBMCs) were cultured with
VEGF, RANKL and M-CSF. VEGF and RANKL together induced differentiation of multinucleated, tartrate-resistant acid phophatase
(TRAP)-positive cells in similar numbers to M-CSF and RANKL. The PBMCs were also able to significantly stimulate resorption of
mineralised matrix after treatment with M-CSF with RANKL and VEGF with RANKL. We have shown that VEGF in the presence of
RANKL supports PBMC differentiation into osteoclast-like cells, able to resorb substrate. Vascular endothelial growth factor may
therefore play a role in physiological bone resorption and in pathological situations. Consequently, VEGF signalling may be a
therapeutic target for osteoclast inhibition in conditions such as tumour osteolysis.
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Skeletal metastases are a common problem in the management of
breast cancer patients. Many such patients suffer from bone pain
and about one-third of patients with bone metastases develop one
or more complications, for example, hypercalcaemia, pathological
fractures or spinal cord compression (Coleman and Rubens, 1987).
Metastatic breast cancer is incurable but its associated morbidity
deserves attention. Understanding the processes involved in
metastasis to bone could lead to optimal management of metastatic
bone disease.
Bone is a unique environment as it is made up of a protein
matrix that is calcified with crystals of hydroxyappatite. This
means that the normal mechanisms that cancer cells use to create
space in the extracellular matrix (ECM), such as the expression of
matrix metalloproteinases (MMP), are ineffective. Therefore,
breast cancer cells are believed to interact with surrounding cells
to promote bone resorption and allow neoplastic invasion.
Vascular endothelial growth factor (VEGF) is an endothelial cell-
specific mitogen (Veikkola and Alitalo, 1999). Binding of VEGF
stimulates endothelial cells to degrade ECM, to migrate and to
form tubes, through its interaction with two main membrane-
bound cell receptors VEGFR1 and VEGFR2 (vascular endothelial
growth factor receptor 1 and 2) (Ortega et al, 1999). Reduction in
tissue oxygen partial pressure (pO2) causes VEGF mRNA
transcription upregulation and stabilisation by osteoblasts (Akeno
et al, 2001) along with some growth factors. Vascular endothelial
growth factor may well not target endothelial cells exclusively as it
has been shown to stimulate lymphocytes, granulocytes and
monocytes, as well as stromal cells (Ortega et al, 1999).
Breast cancer cells have been shown to express VEGF and its
receptors (Jong et al, 1998b). There is evidence to suggest that the
selection and regulation of bony metastases is regulated by
neovascularisation, with a switch from a relatively dormant
metastasis into an ‘angiogenic’ phenotype leading to the produc-
tion of tumour vasculature. This switch appears to be controlled by
a balance of positive and negative angiogenic factors, particularly
VEGF and angiostatin (Folkman, 1995).
Bone metastases from breast cancer tend to be osteolytic.
Evidence supports the current notion that osteoclasts, induced
either directly or indirectly by tumour cells, mediate osteolysis and
that the growth factors released during bone resorption complete a
vicious circle by stimulating tumour growth (Guise, 2000).
Osteolytic bone tumours produce factors that regulate bone
remodelling by altering rates of osteoclast and osteoblast
differentiation and activity leading to a net increase in bone
resorption (Jong et al, 1998a). Osteoclasts, the bone resorbing cells,
are derived from haematopoietic stem cell precursors of the
monocyte/macrophage cell lineage. In vivo, the precursors require
cell to cell interaction with stromal cells expressing the cell
membrane receptor, RANKL, in the presence of M-CSF, in order
that they differentiate into osteoclasts (Yasuda et al, 1998).
Circulating precursors in the mononuclear fraction of peripheral
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sblood have been shown to differentiate into osteoclasts in the
presence of soluble RANKL and M-CSF (Faust et al, 1999;
Shalhoub et al, 1999). RANKL acts on osteoclast precursors via a
membrane receptor, RANK (receptor activator of NF-kB). Recently
a non-RANKL-mediated pathway leading to osteoclastogenesis has
been identified (Itonaga et al, 2004) There is growing evidence of a
link between angiogenesis and bone turnover. Circulating pre-
cursors able to differentiate into endothelial cells are derived from
the monocyte cell lineage, as are osteoclast precursors. Endothelial
cells express similar phenotypic markers to osteoclasts, such as
vitronectin receptor and calcitonin receptor. Recently there have
been studies which show that antiangiogenic factors may inhibit
osteoclast function and tumour osteolysis (Peyruchaud et al,
2003).
Human monocytes have been shown to express the receptors for
VEGF, and VEGF is chemotactic for monocytes (Barleon et al,
1996). Recently, VEGFR1 has been shown to be expressed by
osteoclasts in culture (Sawano et al, 2001). Vascular endothelial
growth factor directly enhances osteoclastic bone resorption and
survival of mature rabbit osteoclasts (Nakagawa et al, 2000). Niida
et al (1999) found that rats, which did not produce M-CSF, were
osteopetrotic as they had no osteoclasts, and that osteoclast
induction could be restored by injection of VEGF. This study also
showed that VEGF could substitute for M-CSF in cultures of rat
bone marrow cells.
The aim of this study was to investigate the role of VEGF in the
development of breast cancer metastases to bone. In this study, we
have used immunohistochemistry to investigate the expression of
VEGF and its receptors by human breast tumours infiltrating bone,
and further characterised the effects of VEGF on osteoclastic
development and activity in vitro.
MATERIALS AND METHODS
Clinical specimens
A total of 17 bone biopsies (12 excisional, five reamings) were
obtained from the Department of Pathology, The Royal Victoria
Infirmary, Newcastle upon Tyne. The biopsies had been taken
from patients undergoing treatment at one of the Newcastle upon
Tyne NHS Hospitals Trust’s hospitals during the period 1993–
2001. Patient ages at the time of biopsy ranged from 34 to 76 years.
Sections of normal endometrium were used as positive controls for
the VEGF and VEGFR1 and VEGFR2. Sections of a bone fracture
were used as a positive control for osteoclasts staining for CD68.
Immunohistochemistry
The specimens were stained with commercially available
antibodies against VEGF and its receptors (VEGF, Flt-1 and KDR
– Santa Cruz Biotechnology, Santa Cruz, CA, USA), and CD68
(DAKO, Denmark, DK-2600 Glostrup, Denmark), to identify
osteoclasts. CD68 was chosen to identify osteoclasts as tartrate-
resistant acid phosphatase (TRAP) staining was not possible
on archived specimens which have been fixed in formalin
and stored for extended periods of time. Alternative markers
(such as vitronectin or calcitonin receptor) were evaluated
as methods but these are markers also found on endothelial
cells. Antigen retrieval was achieved with either microwave
heat-induced antigen retrieval (VEGF and VEGF receptors) or
trypsin (CD68).
After antigen retrieval, the slides underwent a protocol used to
identify the appropriate antigens, modified from the ABC method
initially described by Hsu et al (1981a,b), following the protocol
available from Vectorlabs (Vectorlabs, UK). The sections were
blocked with serum of the same species as the biotinylated
secondary antibody for 20min. The sections were then incubated
for the optimal time with primary antibody diluted in blocking
serum at the optimal concentration in a humidified atmosphere.
Following the incubation with primary antibody, the samples
were washed in PBS. The appropriate biotinylated secondary
antibody was applied for 1h and subsequently the specimens were
incubated with streptavidin biotin complex (ABC) solution for
30min.
The slides were exposed to 1mgml
 1 diaminobenzidine
tetrachloride (DAB – Sigma-Aldrich, Dorset, England, UK)
chromogen for 5min. The slides were then rinsed in running
water and counterstained with Mayer’s haematoxylin (BDH)
(30s) and Scott’s Blue water. The slides were dehydrated and
mounted. Cells that expressed the antigen would stain brown
(DAB).
Cell culture
RAW 264.7 cell line The murine leukaemia virus-induced tumour
monocyte cell line Raw 264.7 was obtained from the American
Type Culture Collection (ATCC, Rockville, USA). This cell line is a
monocyte/macrophage cell line, which has been shown in the past
to differentiate into osteoclasts under stimulation with RANKL and
M-CSF (Wei et al, 2001). Raw 264.7 cells were routinely cultured in
75cm
2 tissue culture flasks (Corning, Stone, UK) in DMEM culture
medium at 371C in an humidified atmosphere containing 5% CO2
in air. Cultures were maintained by subculture in the ratio 1:3 as
required using a cell scraper. RAW 264.7 cells were cultured in
modified Dulbecco’s minimum essential medium (DMEM) (Sig-
ma). In total, 10
4 or 10
3 cells were placed in eight-well chamber
slides (Falcon) in 300ml DMEM and cultured in the presence of
combinations of cytokines (rmVEGF (100ngml
 1), rmM-CSF
(30ngml
 1), rmRANKL (100ngml
 1)) for a period of 1 week
with medium changes every other day.
Peripheral blood mononuclear cells (PBMCs) The isolation of
PBMCs requires the separation of whole blood by centrifugation
through a density gradient (Boyum, 1968a,b). Heparinised blood
was obtained from healthy volunteers with informed consent.
Whole blood was layered onto a sterile aqueous medium
(Histopaque-1077 – Sigma) containing ficoll and sodium diatrizo-
ate at a density of 1.077gml
 1 at 251C. This was then centrifuged
at 500g for 25min at room temperature resulting in the separation
of PBMCs at the blood/ficoll interface, the other white blood cells
(WBC) and red blood cells (RBC) having passed through the
interface. The PBMC interface was collected and washed with
sterile phosphate-buffered saline (PBS) to remove any contam-
inating separation medium. The PBMCs were then pelleted by
centrifugation at 500g for 5min. This pellet was then reconstituted
in a-MEM culture medium.
5 10
5 PBMCs were placed in eight-well chamber slides in
300ml a-MEM and cultured for 2 weeks in the presence of cytokine
combinations (rhVEGF (100ngml
 1), rhM-CSF (30ngml
 1),
rhRANKL (100ngml
 1), Peprotech EC, London W6 8LL, UK).
The medium was changed three times per week.
Following culture, the cells were fixed in 4% paraformaldehyde
and stained for TRAP activity.
Each experiment was repeated three independent times
Tartrate-resistant acid phosphatase staining
Osteoclasts express TRAP, an enzyme, which can be identified
in cells through a histochemical staining methodology (Minkin,
1982; Allen et al, 1989). Staining solution (Sigma Diagnostics)
was made up of acetate, naphthol AS-BI phosphoric acid and
tartrate solution in 371C water and fast garnet GBC salt was
added to the solution. This solution was filtered and the slides
were then incubated in the solution for 1h at 371C and then
washed in water.
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Her Majesty’s Government Customs and Excise (UK) kindly
donated confiscated ivory from illegal trade. The ivory was cut into
7mm square slices 0.8mm thick with a precision cutting saw
(Isomet, Buehler) using diamond-tipped blade. The ivory slices
were sterilised by soaking in 100% ethanol for 1h and thoroughly
washed and exposed for 30min to ultraviolet light to each side of
the square. The slices were then stored in sterile PBS before use.
Peripheral blood mononuclear cells were seeded down onto the
ivory discs in 48-well plates at a density of 5 10
5 cells in 300mlo f
a-MEM per well. The cells were then left to settle for 4h before the
medium was removed entirely and replaced with fresh medium
and the relevant cytokines.
The cells were cultured on ivory for 3 weeks with medium
changes every 3 days. Medium changes replaced two-thirds of the
culture medium.
RAW 264.7 cells were seeded onto the ivory at a density of 10
4
cells per well in 300ml of DMEM. The cells were left overnight, after
which the cytokines were added. The cells were cultured for 2
weeks with medium changes three times per week.
In each individual experiment, treatment groups contained five
separate ivory slices in identical wells. After culture, ivory slices
were fixed in 4% paraformaldehyde and TRAP stained to identify
osteoclasts.
The cells were then removed from the ivory through washing
with 5% sodium hypochlorite and abrasion with cotton wool buds.
Selected individual slices were initially imaged with scanning
electron microscopy to identify resorption pits.
Once resorption had been identified, the slices were viewed
under a reflected light microscope, used for metallurgic imaging.
The images were captured as JPEG files and the area of resorption
could be measured using image analysis (Image J). For quantifica-
tion of each slice, 10 randomly chosen fields of view at 20 times
magnification were captured. Thus for each treatment, 50 images
were analysed (10 fields of view from five slices) giving a mean
area of resorption.
Statistical analysis
Results of the cell culture and resorption assay were processed with
the statistical software Minitab 13 (Minitab Inc.).
RESULTS
Expression of VEGF and its receptors by breast cancer
metastases to bone
All samples stained positively for VEGF and its receptors VEGFR1
and VEGFR2. The osteoclasts were identified as multinucleated
cells associated with bone matrix, which stained positively for
CD68 (a marker of monocyte macrophage cell lineage).
Tumour cells were identified in the sections as those cells that
were abnormal within the section, displaying pleomorphic features
with hyperchromatic nuclei and high nuclear/cytoplasmic ratio. All
sections of bone metastasis from breast cancer, stained with the
antibody against VEGF, localised its expression to the tumour cells
and some bone cells (Figure 1). All the tumour cells stained
strongly and uniformly for VEGF implying high levels of
expression. All sections stained for the receptor VEGFR1 with
staining present in tumour cells and some of the bone cells. The
tumour cells stained uniformly strongly and so there was no
reason to count the cells. VEGFR2 antibody stained all of the
tumour cells with no negative cells visible. Some of the bone cells
stained for this receptor. The endometrium stained with the VEGF,
VEGFR1 and VEGFR2 antibodies showed expression by the
glandular structures as expected but the stroma was negative.
The negative controls showed no staining.
Osteoclasts express VEGF receptors
Osteoclasts were identified in 14 of the 17 sections stained with
antibody to CD68. The three sections with no CD68 staining were
Figure 1 (A) Specimen stained with antibodies against VEGF. The large
pleomorphic tumour cells (arrows) express VEGF at relatively high levels.
Serial sections stained with antibodies against (B) CD68 and (C) VEGFR2.
There is obvious expression of VEGFR2 by the central tumour cells. The
osteoclasts express CD68 (arrows) and can also be seen in (B) to express
VEGFR2.
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sfull of tumour with no bone/tumour interface and hence had no
osteoclasts present. In serial sections it was possible to identify
osteoclasts that were present in more than one section. This
allowed identification of the same osteoclasts, which had been
stained by different antibodies in subsequent sections. Figure 1B
and C shows serial sections staining for the VEGFR2 and CD68
antibodies. Table 1 shows the number of sections where osteoclasts
were identified, and of those, the number of sections where
osteoclasts were identified to express VEGF, VEGF receptors or
CD68. Two specimens had osteoclasts, which did not express
VEGFR1, but all specimens had osteoclasts expressing VEGF and
VEGFR2 to varying degrees. These results are summarised in
Table 1.
Vascular endothelial growth factor supports
differentiation of osteoclasts in the presence of RANKL
By culturing PBMCs in aMEM and in the presence of cytokines
such as RANKL, M-CSF and VEGF, the cells acquire TRAP activity
as demonstrated by the increased numbers of TRAP-positive cells
after the culture period. These TRAP-positive cells can be divided
into mononuclear TRAP-positive and multinucleated TRAP-
positive cells. Mononuclear TRAP-positive cells may be cells on
the pathway to a multinucleated phenotype. In this study, the
osteoclast-like cells were defined as the multinucleated TRAP-
positive cells, as described previously (Matsuzaki et al, 1998;
Shalhoub et al, 1999).
Culture of PBMCs for 2 weeks, while being exposed to
combinations of the cytokines, RANKL, M-CSF and VEGF, resulted
in the formation of multinucleated TRAP-positive cells (Figure 2).
Stimulation of the cells with individual cytokines had little effect,
whereas stimulation by M-CSF (30ngml
 1) and RANKL
(100ngml
 1) or VEGF (100ngml
 1) and RANKL induced
differentiation of significant numbers of osteoclast-like cells, but
there was no difference between these two groups. M-CSF and
VEGF together did not increase the number of multinucleate
TRAP-positive cells (Figure 3).
RAW 264.7 cells cultured for 1 week differentiated into
multinucleated TRAP-positive cells when exposed to certain
combinations of the cytokines, M-CSF (30ngml
 1), VEGF
(100ngml
 1) and RANKL (100ngml
 1). Incubation with M-CSF
and RANKL or VEGF with RANKL resulted in significantly
increased numbers of multinucleated TRAP-positive cells as
compared to negative control (Figure 3).
The individual cytokines and M-CSF with VEGF had
little effect on the numbers of osteoclast-like cells produced
after culture. This is in agreement with the experiments on the
PBMCs.
In these experiments, the numbers of cells that exhibit
osteoclastic phenotype are less than the numbers in the PBMC
cultures. This can be explained by the fact that there were fewer
cells per well initially, but also these cells are an immortalised cell
line that are being stimulated in an attempt to induce terminal
differentiation. The TRAP positivity of these cells was noticeably
reduced compared to the PBMCs and this may be explained by the
same reason.
Table 1 Expression of VEGF, VEGFR1 and VEGFR2 on osteoclasts
present in breast metastases to bone
Patient Osteoclasts present VEGF VEGFR1 VEGFR2
1 + ++ ++ ++
2 + ++ ++ ++
3       
4 + ++ ++ ++
5 + ++ + ++
6 + +++ 0 +
7 + +++ + ++
8 + ++ 0 ++
9       
10 + ++ + ++
11 + ++ ++ ++
12 + ++ ++ +
13 + +++ ++ ++
14 + ++ ++ +++
15 + ++ ++ ++
16       
17 + ++ ++ ++
( )¼no osteoclasts present; (0)¼negative staining; (+)¼weak staining;
(++)¼moderate staining; (+++)¼strong staining; VEGF¼vascular endothelial
growth factor; VEGFR1/2¼vascular endothelial growth factor receptor 1/2.
Figure 2 Tartrate-resistant acid phophatase staining of PBMCs after 2
weeks culture. (A) Negative control, (B) M-CSF and RANKL, (C) VEGF
and RANKL.
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sVascular endothelial growth factor stimulates osteoclasts
to resorb substrate in the presence of RANKL
After 3 weeks of culture under appropriate conditions, the PBMCs
on the ivory slices showed evidence of differentiation into
multinucleated TRAP-positive cells (as expected from previous
culture on eight-well chamber slides). After washing the cells off,
the slices were examined by scanning electron microscopy after
having been coated with gold (Figure 4). The resorption appeared
as characteristic pits in the surface of the ivory. On imaging with a
reflected light microscope, the areas of resorption could again be
identified against the background of machining grooves.
The area of resorption was estimated by delineating the
resorption pits and then processing these images with the image
analysis software. The cells attached to the ivory had been exposed
to the cytokines M-CSF with RANKL and VEGF with RANKL and
these treatments were compared to the negative control of no
treatment. The results can be seen in Figure 5. The areas of
resorption on the slices cultured in M-CSF and VEGF with RANKL
were significantly increased as compared to the slices of the
negative control. There was no significant difference between the
two treatment groups. The cultures were repeated in triplicate and
this result was born out in all three experiments.
The RAW 264.7 cells also differentiated into multinucleated
TRAP-positive cells after culture, as had been seen in the chamber
slide culture. However, the number of resorption pits seen on
electron microscopy was markedly less than with the PBMCs. On
the negative control ivory slices, there was no resorption seen. On
the slices that had been exposed to M-CSF with RANKL and VEGF
with RANKL, there were sparse areas of resorption. However, the
number of pits were too few to make a meaningful count.
DISCUSSION
Vascular endothelial growth factor has been shown to be an
important factor in the progression of solid tumours. As any
tumour grows it outstrips its blood supply and the tumour mass
can become hypoxic. It is at this point that the tumour requires
an ‘angiogenic switch’, where the tumour starts to produce
factors to induce neovascularisation. VEGF has been shown to
be one of the chief factors involved in the development of a







































































M + V + R
A
B
Figure 3 Graph showing mean numbers of multinucleated TRAP-
positive cells after stimulation with cytokines (M¼M-CSF, R¼RANKL,
V¼VEGF). The experiments were carried out in both (A) PBMCs and (B)
RAW 264.7 cells. The experiments were repeated in triplicate and typical
graphs are shown here. Bars in stripes are significantly different on ANOVA
at 95% CI from negative control. Grey bars are significantly different from
positive control (MþR). White bars are different from both.
20 m 
Figure 4 Scanning electron microscopy of ivory slice after culture with




















































Figure 5 Graph showing the mean area of resorption after stimulating
PBMCs for 3 weeks with the cytokines.
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sto express VEGF and it has been identified as a factor, which
conveys a worse prognosis. Levels of VEGF in the circulation
of patients with cancer have been measured and again correlate
with worse prognosis. Primary breast cancer has been studied
by many research groups and VEGF is expressed more with
increasing size and grade of tumour. The breast tumour cells
were also seen to express the VEGF receptors and an autocrine
role for VEGF on breast cancer cells has been hypothesised.
In this study, we have shown not only that metastatic breast
cancer cells in bone express relatively high levels of VEGF
but also that they express VEGF receptors. Furthermore, this
study revealed that osteoclasts associated with breast cancer
metastases express both VEGF receptors. This is in keeping
with the growing evidence available that VEGF has an action
in skeletal biology. Monocytes, the precursors of osteoclasts,
express VEGFR1 (Clauss et al, 1996) and there is some evidence
that VEGFR2 is also expressed (Fernandez Pujol et al, 2000). This
has been shown both at the protein level and the RNA level
(Barleon et al, 1996). In mature osteoclasts, the presence of VEGF
receptors has also been seen. VEGFR1 is seen on rat osteoclasts
(Niida et al, 1999). Both VEGFR1 and VEGFR2 have been detected
at the gene and protein levels in mature osteoclasts (Nakagawa
et al, 2000).
Vascular endothelial growth factor has been shown to act
on monocytes in various ways. Vascular endothelial growth
factor is chemoattractant for monocytes (Barleon et al, 1996;
Clauss et al, 1996; Sawano et al, 2001), and this seems to
be mediated by the VEGFR1. Vascular endothelial growth
factor also stimulates production of tissue factor (a procoagulant)
by monocytes and endothelial cells and this is also mediated
partly by VEGFR1 (Clauss et al, 1996). Interestingly, long-term
stimulation of monocytes with VEGF induces the cells to
differentiate into endothelial-like cells and express increasing
levels of VEGF receptors (Fernandez Pujol et al, 2000). Taken with
the previously reported data, our results show osteoclastic
expression of VEGF receptors and suggest a role for VEGF in
osteoclastic function.
There is growing evidence that VEGF can interact with
monocytes, the precursors of osteoclasts, to induce differentiation
into osteoclasts. Osteopetrotic mice, which lack M-CSF, have no
osteoclasts. An injection of VEGF induces osteoclast recruitment in
a manner similar to M-CSF injection (Niida et al, 1999). Vascular
endothelial growth factor induces preosteoclasts from arthritic
joints to differentiate, migrate and proliferate and this seems to be
mediated by VEGFR1 (Matsumoto et al, 2002). Osteoclastic
induction has also been shown to be increased around moving
teeth when VEGF is administered locally (Kaku et al, 2001).
We have found in our study that VEGF, in the presence of
RANKL can induce differentiation of osteoclasts from human
monocyte precursors isolated from circulating blood from hu-
mans. The experiments have been repeated using the monocyte
cell line, RAW 264.7, with similar results.
Following phenotypic markers allows the study of osteoclasto-
genesis but osteoclast function can only genuinely be assessed by
assessing bone resorption. There is mounting evidence that VEGF
has a role in osteoclast-induced bone resorption. Mature rabbit
osteoclasts cultured on bone slices have increased numbers of
resorption pits after exposure to VEGF (Nakagawa et al, 2000) and
these osteoclasts express both VEGF receptors. The VEGF induced
tyrosine phosphorylation of proteins in the osteoclasts. Nakagawa
et al could not differentiate which receptor mediated this action.
More recently, Henrikson has shown that activity of mouse
osteoclasts can be increased by exposure to VEGF. This was done
by measuring calcium release from metatarsals stimulated with
VEGF and RANKL (Henriksen et al, 2003). The effect of VEGF was
mediated by phosphorylation of ERK1/2 and this was shown to be
necessary as inhibition reduced the effect of VEGF.
Our experiments have revealed that VEGF can substitute for
M-CSF and stimulate the formation of osteoclasts. Vascular
endothelial growth factor and RANKL together induced monocyte
precursors to differentiate and resorb ivory in culture. Therefore,
the localised production of VEGF, such as that observed in
metastatic tissue, is likely to contribute to osteolysis in metastatic
disease.
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